Metabolic-dimension CKM staging and cardiometabolic component burden predicted incident MASLD, with excess adiposity and hypertriglyceridaemia as dominant component-level predictors, while baseline MASLD was not clearly associated with CKM stage progression after accounting for baseline adiposity.
Each additional cardiometabolic component was associated with higher odds of prevalent MASLD in cross-sectional analysis.
Metabolic-dimension CKM Stage 2 was associated with significantly higher incident MASLD risk compared with Stage 0 in the forward cohort.
Excess adiposity was the strongest individual cardiometabolic component predictor of incident MASLD.
Hypertriglyceridaemia was the second strongest individual cardiometabolic component predictor of incident MASLD.
Baseline MASLD was associated with CKM stage progression in an age- and sex-adjusted model, but this association attenuated substantially after adjustment for baseline BMI.
The study was conducted in a community cohort in Guangxi, southern China, using longitudinal health examination data.
This research suggests that people who have more cardiovascular and metabolic risk factors — such as obesity, high triglycerides, high blood pressure, high blood sugar, and low HDL cholesterol — face a significantly higher risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), a common form of fatty liver disease. Using data from over 2,000 adults in southern China who were followed for about two and a half years, the study found that those with the highest burden of these risk factors (classified as CKM Stage 2) were more than twice as likely to develop MASLD compared to those with none. Of all the individual risk factors examined, excess body weight was by far the strongest predictor, followed by high triglyceride levels in the blood. The study also explored whether having MASLD at the start of the study predicted worsening of cardiovascular and metabolic risk over time. While MASLD did appear to predict such progression when only age and sex were accounted for, this association largely disappeared once body weight (BMI) was taken into account. This suggests that it may be excess adiposity — rather than MASLD itself — that drives further metabolic deterioration, at least over this relatively short follow-up period. This research matters because it highlights the close relationship between fatty liver disease and broader cardiovascular-metabolic health. The findings suggest that monitoring and addressing cardiometabolic risk factors — especially excess weight and high triglycerides — may be important for preventing fatty liver disease in the general population. The study also reinforces that MASLD and metabolic syndrome share overlapping biological pathways, making it difficult to fully separate their individual contributions to health outcomes.
Long X, Wu M, Mo Y, Zhang Y, Lin Y, Zhang Q, et al.. (2026). Metabolic-dimension CKM staging and cardiometabolic components predict incident MASLD: a longitudinal community-based cohort study.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1847134